ClinicalTrials.gg
Status unknownNCT04191213GA&SCAUpdated Jan 28, 2020

Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients

A Phase 2/3 interventional study of Acacia Senegal extract and Pectin in Sickle Cell Anemia in Children, sponsored by Al-Neelain University. Status unknown at 1 site in Sudan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Al-Neelain University · Phase 2/3, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo

Read the detailed description

Polymerized hemoglobin is injurious to the red cell membrane, resulting in oxidative damage in sickle cell disease . Fetal hemoglobin is protective against sickling and its decrease is associated with vaso-occlusive crisis . Gum Arabic is soluble fibers with prebiotic properties. It increased the level of serum butyrate which is short chain fatty acid. The latter proved to serve as fetal hemoglobin inducing agent both in vivo and in vitro study. And also has strong anti-inflammatory properties. So our aim to test whether oral digestion of Gum Arabic will induce fetal hemoglobin among sickle cell pediatric patients

02

Conditions studied

  • Sickle Cell Anemia in Children

Keywords

  • sickle cell anemia
  • Gum Arabic
  • Fetal Hemoglobin
03

In context

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

This study's planned enrollment of 100 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.

Browse Anemia, Sickle Cell studies →

Lead sponsor

Al-Neelain University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous for Sickle Cell Disease (SS) as documented by electrophoresis.

Subjects whom medications and dosages had been stable for 2 weeks before study entry.

Subjects who have not received blood transfusion or had acute episode related to sickle cell disease in the last two weeks before the start of intervention.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of Gum Arabic allergy. Patients who have ischemic heart disease, liver dysfunction or hepatitis. Pregnant female patients who plan to conceive in the next 4 months and fertile female patients who are not using an effective method.

Patients who are currently using Gum Arabic. Patients who are on or chemotherapy.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks

    Dietary Supplement: Acacia Senegal extract

  • Placebo comparator
    Control group

    This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age \& two-gram-dose for children above 5 years of age

    Dietary Supplement: Pectin

Interventions

  • Dietary supplementAcacia Senegal extract

    Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks

    Also known as: (Gum Arabic)

  • Dietary supplementPectin

    Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks

06

What researchers measure

Primary outcomes

  1. Fetal hemoglobin level after 12 weeks

    Measure increase from the baseline values

    Time frame: 12 weeks

  2. Total anti oxidant capacity

    Measure increase from the baseline values

    Time frame: 12 weeks

Secondary outcomes

  1. Anti inflammatory marker C reactive Protein

    Measure decrease from the baseline values

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Military Hospital
    Omdurman, Khartoum 1113, Sudan
    Recruiting
    • Haydar A Abdelrazig, MD · Contacthabdelhakam1@hotmail.com · 249123431031
    • Haydar A Abdelrazig, MD · Sub investigator
    • Dalya MM Abdelmaged, MBBS · Principal investigator
    • Lamis AA Kaddam, PhD · Sub investigator
08

References and documents

Publications

  • Kaddam L, FdleAlmula I, Eisawi OA, Abdelrazig HA, Elnimeiri M, Lang F, Saeed AM. Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study. BMC Hematol. 2015 Dec 29;15:19. doi: 10.1186/s12878-015-0040-6. eCollection 2015. PubMed 26719803 ↗
  • Kaddam L, Fadl-Elmula I, Eisawi OA, Abdelrazig HA, Salih MA, Lang F, Saeed AM. Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial. BMC Hematol. 2017 Mar 16;17:4. doi: 10.1186/s12878-017-0075-y. eCollection 2017. PubMed 28331623 ↗
  • Kamal E, Kaddam LA, Dahawi M, Osman M, Salih MA, Alagib A, Saeed A. Gum Arabic Fibers Decreased Inflammatory Markers and Disease Severity Score among Rheumatoid Arthritis Patients, Phase II Trial. Int J Rheumatol. 2018 Jul 5;2018:4197537. doi: 10.1155/2018/4197537. eCollection 2018. PubMed 30112005 ↗

Individual participant data

Plan to share: Undecided — Share patients data without personal data and without breaching confidentiality

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04191213
Lead sponsor
Al-Neelain University
Collaborators
University of Khartoum
Responsible party
Lamis Kaddam (Director, Al-Neelain University) — Principal investigator
First posted
Dec 9, 2019
Start date
Feb 15, 2020 (estimated)
Primary completion
Jun 15, 2020 (estimated)
Completion
Jul 15, 2020 (estimated)
Last update
Jan 28, 2020

Study contacts

Dalya MM Abdelmaged, MBBS
Contact
dalya.alfeel@gmail.com
00249126831595
Lamis AA KAddam, PhD
Contact
lamiskaddam@hotmail.com
+249912979736
Imad M Fdl-Elmula, PhD
study director · Alneelain University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion